Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients with Malignancies Dependent on Wnt Ligands

Summary

06/28/2018 NOTE: Sites may be enrolling in different cohorts. The purpose of this phase I trial is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies for whom no effective standard treatment is available. Biomarker testing to determine if patient is eligible for the trial will be done during pre-screening for the trial; however,prior reports may be acceptable.

General Information

NCT#: NCT01351103
Study ID: CLGK974X2101
Trial Phase: Phase I

Trial Sponsor: Novartis Pharmaceuticals
Therapies Used in This Trial: LGK974, Spartalizumab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search